TransMedics Group, Inc. (NASDAQ:TMDX) Receives $144.25 Consensus Target Price from Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $144.25.

A number of analysts have weighed in on TMDX shares. Morgan Stanley increased their price target on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Needham & Company LLC boosted their price target on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Jefferies Financial Group assumed coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 price target on the stock. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th.

Insider Transactions at TransMedics Group

In other news, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at $2,026,545.10. This trade represents a 17.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the sale, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,920 shares of company stock valued at $1,257,310 in the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC raised its holdings in TransMedics Group by 28.9% during the 2nd quarter. Intech Investment Management LLC now owns 34,389 shares of the company’s stock valued at $4,608,000 after acquiring an additional 7,713 shares during the period. Valmark Advisers Inc. grew its position in shares of TransMedics Group by 34.6% in the second quarter. Valmark Advisers Inc. now owns 9,709 shares of the company’s stock valued at $1,301,000 after purchasing an additional 2,496 shares in the last quarter. Nordea Investment Management AB bought a new stake in shares of TransMedics Group during the 3rd quarter valued at $4,070,000. Peregrine Capital Management LLC raised its stake in shares of TransMedics Group by 16.5% during the 3rd quarter. Peregrine Capital Management LLC now owns 68,406 shares of the company’s stock valued at $7,675,000 after purchasing an additional 9,676 shares during the period. Finally, Intrust Bank NA purchased a new stake in TransMedics Group during the 2nd quarter worth about $747,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Price Performance

Shares of TMDX opened at $135.72 on Wednesday. The business has a 50-day moving average of $133.97 and a 200-day moving average of $124.06. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The company has a market capitalization of $4.64 billion, a price-to-earnings ratio of 54.95 and a beta of 2.06. TransMedics Group has a 1 year low of $62.07 and a 1 year high of $156.00.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.